GE HealthCare Technologies (GEHC) Research & Development (2022 - 2026)

GE HealthCare Technologies (GEHC) has reported Research & Development for 5 consecutive years, with $323.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 6.95% year-over-year to $323.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.3 billion (down 1.76% YoY), and the FY2025 full-year result was $1.3 billion, down 3.89% from the prior year.
• Research & Development slipped to $323.0 million in Q2 2026 per GEHC's latest filing, from $345.0 million in the prior quarter.
• Across five years, Research & Development topped out at $345.0 million in Q1 2026 and bottomed at $238.0 million in Q1 2022.
• Historically, Research & Development has averaged $303.9 million across 5 years, with a median of $315.5 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Research & Development advanced 23.85% in 2023, then slipped 7.65% in 2025.
• Over 5 years, Research & Development stood at $271.0 million in 2022, then gained by 16.24% to $315.0 million in 2023, then gained by 9.21% to $344.0 million in 2024, then fell by 6.1% to $323.0 million in 2025, then changed by 0.0% to $323.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $323.0 million, $345.0 million, and $323.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.